×
Please click
here
if you are not redirected within a few seconds.
All
News
Maps
Images
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Yahoo Finance
SAN DIEGO, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused...
2 months ago
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual ...
GlobeNewswire
The oral presentation will focus on topline Stage 1 data from both arms of the relapsed or refractory EBV+ peripheral T-cell lymphoma cohort...
1 month ago
Viracta Therapeutics Provides Clinical Update and Outlook for 2024
Yahoo Finance
Speed to market strategy for Nana-val in patients with relapsed or refractory EBV+ peripheral T-cell lymphoma supported by complete...
3 months ago
Viracta Therapeutics Loses Finance, Operating Chief
MarketWatch
By Ben Glickman Viracta Therapeutics said its finance and operating chief Dan Chevallard has resigned from his dual roles to pursue other...
1 month ago
Why Is Viracta Therapeutics Stock Trading Lower Today? - Viracta Therapeutics (NASDAQ:VIRX)
Benzinga
Monday, Viracta Therapeutics Inc. VIRX+4.55%. + Free Alerts. reported topline results from Stage 1 of the pivotal Phase 2 NAVAL-1 trial from...
2 weeks ago
Viracta Therapeutics CFO Resigns, Interim Successor Appointed - TipRanks.com
Tipranks
Viracta Therapeutics (VIRX) has provided an update. Viracta Therapeutics, Inc. announced the resignation of Dan Chevallard as CFO and COO,...
1 month ago
Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with ...
GlobeNewswire
Patients in the Nana-val (nanatinostat in combination with valganciclovir) treatment arm achieved clinically meaningful anti-tumor responses...
2 weeks ago
Thinking about buying stock in Quantum-Si, Victoria's Secret, Viracta Therapeutics, CERo Therapeutics, or ...
MarketScreener
NEW YORK, March 8, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for QSI, VSCO, VIRX, CERO, and WY. ...
1 month ago
Viracta demonstrates promising and durable signal of EBV+ drug candidate
Clinical Trials Arena
Viracta announces that EBV+ lymphoma patients achieved a 19% complete response and a 40% overall response to Nana-val in a Phase Ib/II...
8 months ago
VIRX Stock Earnings: Viracta Therapeutics Misses EPS for Q4 2023
InvestorPlace
VIRX stock results show that Viracta Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.
1 month ago